Nonhematologic grade 3/4 toxicities of treated patients
| n (%) | All patients (N = 57) | Responders OR (N = 23) | Nonresponders NR (N = 34) | P-value OR vs. NR |
|---|---|---|---|---|
| Pulmonary congestion | 27 (47%) | 10 (43%) | 17 (50%) | .629 |
| Renal failure | 11 (19%) | 5 (22%) | 6 (18%) | .701 |
| Prolonged hypotension | 13 (23%) | 5 (22%) | 8 (24%) | .874 |
| Hyperbilirubinemia | 8 (14%) | 5 (22%) | 3 (9%) | .181 |
| Diarrhea | 7 (12%) | 3 (13%) | 4 (12%) | .885 |
| Cardiac toxicity | 1 (2%) | 1 (4%) | 0 | .404 |
| Confusion | 4 (7%) | 3 (13%) | 1 (3%) | .289 |
| Skin rash | 2 (4%) | 2 (9%) | 0 | .158 |
| Autoimmunity (vitiligo) | 1 (2%) | 1 (4%) | 0 | .404 |
| Mortality (cardiac arrest; one additional patient died during preconditioning) | 1 | na | na | na |
NOTE: Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0.
Abbreviation: na, not applicable.